Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

LRMR

Larimar Therapeutics Inc

Apr 26 • 04:00PM ET

6.44

Dollar change +0.11
Percentage change 1.74	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWM IWN VTWO ITOT IWC AVSC VTWV DFAC

Index	RUT	P/E	-	EPS (ttm)	-0.84	Insider Own	41.05%	Shs Outstand	43.91M	Perf Week	-1.38%
Market Cap	410.87M	Forward P/E	-	EPS next Y	-1.90	Insider Trans	19.63%	Shs Float	37.61M	Perf Month	-11.36%
Income	-36.95M	PEG	-	EPS next Q	-0.24	Inst Own	40.10%	Short Float	9.66%	Perf Quarter	31.70%
Sales	0.00M	P/S	-	EPS this Y	-49.35%	Inst Trans	72.24%	Short Ratio	5.63	Perf Half Y	119.05%
Book/sh	1.86	P/B	3.46	EPS next Y	-51.69%	ROA	-33.24%	Short Interest	3.63M	Perf Year	42.48%
Cash/sh	1.36	P/C	4.73	EPS next 5Y	-	ROE	-38.36%	52W Range	2.18 - 13.68	Perf YTD	41.54%
Dividend Est.	-	P/FCF	-	EPS past 5Y	48.33%	ROI	-42.75%	52W High	-52.92%	Beta	0.98
Dividend TTM	-	Quick Ratio	9.49	Sales past 5Y	0.00%	Gross Margin	-	52W Low	195.41%	ATR (14)	0.53
Dividend Ex-Date	-	Current Ratio	9.49	EPS Y/Y TTM	45.68%	Oper. Margin	0.00%	RSI (14)	36.74	Volatility	5.88% 7.16%
Employees	42	Debt/Eq	0.07	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	22.40
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	-37.82%	Payout	-	Rel Volume	0.22	Prev Close	6.33
Sales Surprise	-	EPS Surprise	-20.82%	Sales Q/Q	-	Earnings	Mar 14 AMC	Avg Volume	645.59K	Price	6.44
SMA20	-8.18%	SMA50	-28.16%	SMA200	23.89%	Trades		Volume	144,013	Change	1.74%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-03-24	Initiated	Leerink Partners	Outperform	$25
Nov-17-23	Upgrade	Citigroup	Neutral → Buy	$4.50
Oct-19-22	Initiated	Guggenheim	Buy	$12
Feb-15-22	Downgrade	William Blair	Outperform → Mkt Perform
Feb-10-21	Initiated	JMP Securities	Mkt Outperform
Feb-01-21	Initiated	William Blair	Outperform	$29

Mar-20-24 01:32PM	Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks (Insider Monkey)
Mar-14-24 09:53PM	LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -6.51%
05:32PM	Larimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
04:05PM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development (GlobeNewswire)
Mar-11-24 04:05PM	Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia (GlobeNewswire) -15.39%
04:05PM	Loading…
Mar-06-24 04:05PM	Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-20-24 01:47PM	Hedge Fund and Insider Trading News: Bill Ackman, George Soros, Arkhouse Management, TYR Capital, Borea Asset Management, Larimar Therapeutics, Inc. (LRMR), and More (Insider Monkey) -5.63%
Feb-19-24 01:48PM	Hedge Fund and Insider Trading News: Bill Ackman, David Tepper, Mark Yusko, Elliott Management, Conestoga Capital Advisors, Larimar Therapeutics Inc (LRMR), Agree Realty Corporation (ADC), and More (Insider Monkey)
Feb-16-24 04:20PM	Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Feb-14-24 06:15AM	Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock (GlobeNewswire) +36.84%
Feb-13-24 04:18PM	Larimar Therapeutics Announces Proposed Underwritten Public Offering (GlobeNewswire) +11.62%
Feb-12-24 07:00AM	Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia (GlobeNewswire)
Nov-14-23 07:00AM	Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results (GlobeNewswire) +7.11%
Nov-01-23 04:05PM	Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference (GlobeNewswire)
Oct-03-23 04:05PM	Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors (GlobeNewswire) -5.83%
04:05PM	Loading…
Aug-31-23 04:05PM	Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference (GlobeNewswire)
Aug-10-23 07:00AM	Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results (GlobeNewswire)
Aug-07-23 09:22AM	Larimar Therapeutics Insiders Placed Bullish Bets Worth US$1.2m (Simply Wall St.) -7.19%
Jul-25-23 09:59AM	These 2 Strong Buy Penny Stocks Could Go Boom, Say Analysts (TipRanks) +7.67%
07:00AM	Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial (GlobeNewswire)
Jul-17-23 04:05PM	Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer (GlobeNewswire)
Jun-21-23 04:05PM	Larimar Therapeutics Set to Join Russell 3000® Index (GlobeNewswire)
May-15-23 07:00AM	Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trials 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreichs Ataxia and First Quarter 2023 Financial Results (GlobeNewswire) -29.05%
Mar-28-23 04:05PM	Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days (GlobeNewswire)
Mar-14-23 07:00AM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results (GlobeNewswire)
Feb-07-23 04:05PM	Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer (GlobeNewswire) +6.52%
Nov-21-22 04:05PM	Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-10-22 07:00AM	Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results (GlobeNewswire)
Nov-07-22 04:05PM	Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day (GlobeNewswire)
Oct-20-22 08:00AM	Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601 (GlobeNewswire)
04:05PM	Loading…
Oct-19-22 04:05PM	Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research (GlobeNewswire)
Sep-16-22 01:00PM	Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares (GlobeNewswire) -5.04%
Sep-14-22 07:04AM	Larimar Therapeutics Announces $70 Million Underwritten Offering (GlobeNewswire) +15.56%
07:01AM	Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreichs Ataxia Patients (GlobeNewswire)
Aug-11-22 04:05PM	Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results (GlobeNewswire)
Jul-28-22 04:05PM	Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders (GlobeNewswire)
Jun-28-22 08:00AM	Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts (GlobeNewswire)
06:05AM	We're Keeping An Eye On Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Rate (Simply Wall St.)
Jun-02-22 08:00AM	Larimar Therapeutics Announces Upcoming Scientific Conference Presentations (GlobeNewswire)
May-19-22 08:00AM	Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinsons Disease and Movement Disorders Congress (GlobeNewswire)
May-12-22 07:00AM	Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results (GlobeNewswire) -7.91%
Apr-29-22 06:27AM	Despite recent gains, Larimar Therapeutics, Inc. (NASDAQ:LRMR) insiders are still down US$273k after purchasing last year (Simply Wall St.) -5.84%
Apr-13-22 10:40AM	Down 21.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Larimar (LRMR) (Zacks)
Mar-25-22 07:00AM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results (GlobeNewswire)
Feb-16-22 11:57AM	Larimar Therapeutics' stock plunges on FDA decision; could implement cost-cutting measures (American City Business Journals)
Feb-14-22 04:01PM	Larimar Therapeutics Provides Update on CTI-1601 Clinical Program (GlobeNewswire)
Jan-19-22 06:53AM	Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Nov-22-21 07:00AM	Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference (GlobeNewswire)
Nov-20-21 08:40AM	In spite of Larimar Therapeutics, Inc.'s recent pullback, insiders still gained about US$85k after buying earlier this year. (Simply Wall St.)
Nov-15-21 07:00AM	Larimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology Conference (GlobeNewswire)
Nov-12-21 07:00AM	Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results (GlobeNewswire) -8.72%
Sep-16-21 08:00AM	Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event (GlobeNewswire) -7.48%
Sep-02-21 04:01PM	Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference (GlobeNewswire) +5.81%
Aug-22-21 10:12AM	What You Need To Know About Larimar Therapeutics, Inc.'s (NASDAQ:LRMR) Investor Composition (Simply Wall St.)
Aug-19-21 07:00AM	Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress (GlobeNewswire)
Aug-12-21 07:00AM	Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results (GlobeNewswire) +17.79%
Aug-09-21 08:48AM	Why Larimar (LRMR) Might Surprise This Earnings Season (Zacks)
Jul-23-21 12:00PM	Larimar (LRMR) Upgraded to Buy: Here's Why (Zacks)
Jul-08-21 04:01PM	Larimar Therapeutics to Present at the William Blair Biotech Focus Conference 2021 (GlobeNewswire)
Jun-11-21 07:00AM	Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference (GlobeNewswire)
Jun-05-21 07:55PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR (Newsfile)
Jun-02-21 10:56PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR (GlobeNewswire)
Jun-01-21 04:55AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR (PR Newswire)
May-29-21 10:59PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR (Newsfile)
May-25-21 05:41PM	Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing (GlobeNewswire) -10.59%
May-21-21 09:18AM	Larimar Therapeutics Announces $95 Million Private Placement Financing (GlobeNewswire) +11.17%
May-20-21 04:31PM	Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreichs Ataxia (GlobeNewswire) +10.17%
May-11-21 07:00AM	Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreichs Ataxia (GlobeNewswire) -36.28%
May-10-21 04:05PM	Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results (GlobeNewswire) -5.34%
Mar-04-21 07:00AM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results (GlobeNewswire)
Mar-01-21 03:54AM	Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation (Simply Wall St.)
Feb-18-21 04:01PM	Larimar Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference (GlobeNewswire)
Dec-16-20 07:23PM	Is LRMR A Good Stock To Buy Now? (Insider Monkey)
Dec-15-20 08:00AM	Larimar Therapeutics Added to NASDAQ Biotechnology Index (GlobeNewswire)
Dec-08-20 07:30AM	Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreichs Ataxia Patients and Provides Program Update (GlobeNewswire)
Nov-13-20 08:00AM	Larimar Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +16.58%
Nov-10-20 08:00AM	Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results (GlobeNewswire) -6.12%
Oct-14-20 10:18PM	Hedge Funds Are Betting On Larimar Therapeutics, Inc. (LRMR) (Insider Monkey)
Oct-13-20 08:00AM	Larimar Therapeutics Announces Formation of Scientific Advisory Board (GlobeNewswire) +22.55%
Sep-21-20 09:58AM	Larimar Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (GlobeNewswire) -6.19%
Sep-10-20 08:00AM	Larimar Therapeutics to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference (GlobeNewswire) +7.50%
Sep-01-20 12:47PM	What Is The Ownership Structure Like For Larimar Therapeutics, Inc. (NASDAQ:LRMR)? (Simply Wall St.)
Aug-11-20 07:00AM	Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results (GlobeNewswire) +9.43%
Aug-04-20 08:00AM	Larimar Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jul-28-20 08:00AM	Larimar Therapeutics Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CTI-1601 for the Treatment of Friedreichs Ataxia (GlobeNewswire)
Jul-20-20 04:15PM	Larimar Therapeutics Announces Dosing of Patients in Third Cohort of Phase 1 SAD Trial of CTI-1601 for Treatment of Friedreichs Ataxia (GlobeNewswire)
May-29-20 04:05PM	Larimar Therapeutics to Present at Jefferies Virtual Healthcare Conference (GlobeNewswire)

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Flynn James E	Director	Feb 16 '24	Buy	8.74	4,290,617	37,499,993	6,151,406	Feb 16 02:37 PM
THOMAS FRANK E	Director	Feb 14 '24	Buy	11.00	2,000	22,000	2,000	Feb 15 04:21 PM
Shankar Gopi	Chief Development Officer	Dec 07 '23	Buy	3.73	5,000	18,662	5,000	Dec 08 04:08 PM
Celano Michael	Chief Financial Officer	May 17 '23	Buy	3.73	5,000	18,632	112,746	May 18 02:13 PM
BEN-MAIMON CAROLE	President and CEO	May 17 '23	Buy	3.71	5,000	18,525	266,829	May 18 02:13 PM
Truitt Joseph	Director	May 17 '23	Buy	3.73	2,750	10,258	2,750	May 18 02:12 PM

Open in Screener

OSUR

Orasure Technologies Inc.

Apr 26 • 04:00PM ET

5.32

Dollar change +0.06
Percentage change 1.14	%

Healthcare • Medical Instruments & Supplies • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

OSUR Orasure Technologies Inc. daily Stock Chart

Held by: IJR VTI IWM AVUV VXF IJT IWN XSVM DFAT VIOO

Index	RUT	P/E	7.39	EPS (ttm)	0.72	Insider Own	3.67%	Shs Outstand	73.53M	Perf Week	0.76%
Market Cap	392.62M	Forward P/E	-	EPS next Y	-0.07	Insider Trans	-0.88%	Shs Float	71.09M	Perf Month	-13.36%
Income	53.66M	PEG	0.37	EPS next Q	0.06	Inst Own	94.23%	Short Float	4.72%	Perf Quarter	-29.91%
Sales	405.47M	P/S	0.97	EPS this Y	-	Inst Trans	-4.15%	Short Ratio	3.65	Perf Half Y	-1.85%
Book/sh	5.86	P/B	0.91	EPS next Y	-	ROA	11.57%	Short Interest	3.35M	Perf Year	-19.88%
Cash/sh	3.94	P/C	1.35	EPS next 5Y	20.00%	ROE	13.51%	52W Range	4.38 - 8.45	Perf YTD	-35.12%
Dividend Est.	-	P/FCF	2.99	EPS past 5Y	17.20%	ROI	12.14%	52W High	-37.04%	Beta	0.23
Dividend TTM	-	Quick Ratio	8.57	Sales past 5Y	20.54%	Gross Margin	42.46%	52W Low	21.60%	ATR (14)	0.20
Dividend Ex-Date	-	Current Ratio	9.77	EPS Y/Y TTM	393.46%	Oper. Margin	10.83%	RSI (14)	33.14	Volatility	2.66% 3.13%
Employees	638	Debt/Eq	0.03	Sales Y/Y TTM	4.64%	Profit Margin	13.23%	Recom	2.67	Target Price	7.55
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	25.99%	Payout	0.00%	Rel Volume	0.58	Prev Close	5.26
Sales Surprise	2.37%	EPS Surprise	165.75%	Sales Q/Q	-38.35%	Earnings	Feb 27 AMC	Avg Volume	919.69K	Price	5.32
SMA20	-6.15%	SMA50	-16.52%	SMA200	-17.42%	Trades		Volume	534,356	Change	1.14%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-03-23	Resumed	Evercore ISI	In-line	$5
Sep-22-21	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-21-20	Initiated	Evercore ISI	Outperform	$22
Aug-10-20	Initiated	JP Morgan	Neutral	$18
Aug-10-20	Initiated	Citigroup	Buy	$18
Aug-07-20	Upgrade	Raymond James	Mkt Perform → Outperform	$16
Jun-25-20	Initiated	Lake Street	Buy	$19
Apr-21-20	Resumed	Stephens	Equal-Weight	$14
Oct-23-18	Resumed	Raymond James	Mkt Perform
Jul-16-18	Downgrade	Stephens	Overweight → Equal-Weight
Nov-02-17	Downgrade	Jefferies	Buy → Hold
Feb-09-17	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-13-16	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-05-15	Reiterated	Mizuho	Buy	$12 → $8
May-07-15	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jan-23-15	Reiterated	Mizuho	Buy	$10 → $12
Jun-12-14	Reiterated	Canaccord Genuity	Buy	$10 → $11
Jun-11-14	Reiterated	Mizuho	Buy	$9 → $10
Dec-21-12	Initiated	Mizuho	Buy	$9
Aug-08-12	Upgrade	Barrington Research	Mkt Perform → Outperform	$12.50

Show Previous Ratings

Apr-22-24 08:00AM	OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th (GlobeNewswire)
Apr-18-24 11:30AM	Wall Street Favorites: 3 Under-$10 Stocks With Strong Buy Ratings for April 2024 (InvestorPlace)
Mar-21-24 08:31AM	NOWDiagnostics Welcomes Dr. Stephen S. Tang as Chairman of the Board (Business Wire)
Feb-28-24 09:23AM	Q4 2023 OraSure Technologies Inc Earnings Call (Thomson Reuters StreetEvents) +9.96%
08:55AM	OraSure Technologies, Inc. (NASDAQ:OSUR) Q4 2023 Earnings Call Transcript (Insider Monkey)
05:11PM	Loading…
Feb-27-24 05:11PM	OraSure: Q4 Earnings Snapshot (Associated Press Finance)
04:48PM	OraSure Technologies Inc (OSUR) Reports Q4 Revenue Decline Amidst Strategic Growth Efforts (GuruFocus.com)
04:05PM	OraSure Reports Q4 '23 Revenue of $75.9 Million (GlobeNewswire)
Feb-13-24 04:05PM	OraSure to Announce Fourth Quarter 2023 Financial Results and Host Earnings Call on February 27th (GlobeNewswire) -5.03%
Feb-01-24 06:42PM	3 Strong Buy Stocks Under $10: January 2024 (InvestorPlace)
Jan-04-24 07:05AM	OraSure Technologies, Inc. Secures Strategic Distribution Rights and Invests in Sapphiros, a Next-Generation Consumer Diagnostics Company (GlobeNewswire)
Dec-22-23 05:01AM	Insider Sell: Chief Product Officer Kathleen Weber Sells 24,129 Shares of OraSure Technologies Inc (GuruFocus.com)
Nov-27-23 09:55AM	After Golden Cross, OraSure Technologies (OSUR)'s Technical Outlook is Bright (Zacks)
Nov-13-23 04:15PM	OraSure to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-09-23 11:12AM	7 Healthcare Stocks That Are Poised to Become the Next Unicorns (InvestorPlace)
12:14PM	Loading…
Nov-08-23 12:14PM	OraSure Technologies, Inc. (NASDAQ:OSUR) Q3 2023 Earnings Call Transcript (Insider Monkey)
08:40AM	Q3 2023 OraSure Technologies Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 06:50PM	OraSure Technologies (OSUR) Tops Q3 Earnings and Revenue Estimates (Zacks)
05:47PM	OraSure: Q3 Earnings Snapshot (Associated Press Finance)
04:59PM	OraSure Technologies Inc (OSUR) Q3 Earnings: Core Business Grows Amidst Decline in COVID-19 Revenue (GuruFocus.com)
04:05PM	OraSure Reports Q3 23 Revenue of $89.2 Million; Core Revenue Grows 7% Year-over-Year (GlobeNewswire)
Oct-23-23 04:05PM	OraSure to Announce Third Quarter 2023 Financial Results and Host Earnings Call on November 7th (GlobeNewswire)
Aug-09-23 06:02AM	Industry Analysts Just Made A Sizeable Upgrade To Their OraSure Technologies, Inc. (NASDAQ:OSUR) Revenue Forecasts (Simply Wall St.)
Aug-05-23 08:52AM	OraSure Technologies, Inc.'s (NASDAQ:OSUR) Intrinsic Value Is Potentially 57% Above Its Share Price (Simply Wall St.)
Aug-04-23 11:45AM	Q2 2023 OraSure Technologies Inc Earnings Call (Thomson Reuters StreetEvents) +32.29%
Aug-03-23 05:55PM	OraSure Technologies (OSUR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:58PM	OraSure: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	OraSure Reports Q2 23 Revenue of $85.4 Million; Core Revenue Grows 3% Year-over-Year (GlobeNewswire)
Jul-20-23 04:05PM	OraSure to Announce Second Quarter 2023 Financial Results and Host Earnings Call on August 3rd (GlobeNewswire)
07:05AM	OraSure Technologies Elects Robert McMahon to the Board of Directors (GlobeNewswire)
07:07AM	Loading…
Jun-29-23 07:07AM	OraSure Technologies' (NASDAQ:OSUR) investors will be pleased with their favorable 82% return over the last year (Simply Wall St.)
Jun-21-23 08:00PM	OSUR: What does Argus have to say about OSUR? (Argus Research)
Jun-13-23 04:05PM	Study Concludes Self-Sampling Using Colli-Pee® Device for HPV Screening Is Both Cost Effective and Could Improve Patient Access (GlobeNewswire)
Jun-08-23 11:03AM	OraSure Technologies (NASDAQ:OSUR) Has More To Do To Multiply In Value Going Forward (Simply Wall St.)
Jun-01-23 06:29AM	Daily Vickers Top Buyers & Sellers for 06/01/2023 (Argus Research) +9.94%
May-16-23 06:08AM	Time To Worry? Analysts Just Downgraded Their OraSure Technologies, Inc. (NASDAQ:OSUR) Outlook (Simply Wall St.)
May-12-23 07:12AM	Can Mixed Fundamentals Have A Negative Impact on OraSure Technologies, Inc. (NASDAQ:OSUR) Current Share Price Momentum? (Simply Wall St.) -18.67%
May-11-23 11:03AM	Q1 2023 OraSure Technologies Inc Earnings Call (Thomson Reuters StreetEvents)
May-10-23 05:35PM	OraSure Technologies (OSUR) Q1 Earnings and Revenues Beat Estimates (Zacks)
04:34PM	OraSure: Q1 Earnings Snapshot (AP Finance)
04:05PM	OraSure Reports 1Q23 Record Revenue of $155.0 Million; Announces New Collaborations as Company Increasingly Focuses on Core Growth (GlobeNewswire)
May-03-23 07:05AM	2023 First Quarter Earnings Conference Call Wednesday, May 10, 2023, 5:00 p.m. ET (GlobeNewswire)
Apr-26-23 08:00PM	OSUR: What does Argus have to say about OSUR? (Argus Research)
Apr-21-23 09:40AM	Is OraSure Technologies (OSUR) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-05-23 08:38AM	OraSure (OSUR) Stock Jumps 9.3%: Will It Continue to Soar? (Zacks)
Mar-29-23 07:30AM	We're Hopeful That OraSure Technologies (NASDAQ:OSUR) Will Use Its Cash Wisely (Simply Wall St.)
Mar-21-23 07:22AM	Zacks.com featured highlights include OraSure Technologies, Compania de Minas Buenaventura SAA and Vipshop (Zacks)
Mar-20-23 07:20AM	3 Low-Beta Stocks to Buy to Combat the Volatile Market (Zacks)
Mar-08-23 11:53AM	OraSure Technologies, Inc. (NASDAQ:OSUR) is a favorite amongst institutional investors who own 79% (Simply Wall St.)
Feb-23-23 12:20PM	Surging Earnings Estimates Signal Upside for OraSure (OSUR) Stock (Zacks)
Feb-16-23 04:38PM	OraSure Technologies, Inc. (NASDAQ:OSUR) Q4 2022 Earnings Call Transcript (Insider Monkey)
05:41AM	OraSure Technologies Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Feb-15-23 03:48PM	Why OraSure Technologies Stock Is Jumping Today (Motley Fool) +12.17%
Feb-14-23 06:05PM	OraSure Technologies (OSUR) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
04:05PM	OraSure Reports 4Q22 Record Revenue of $123.1 Million Growing 94% Year-Over-Year; Positions for Longer-Term Growth and Profitability (GlobeNewswire)
Feb-07-23 07:05AM	2022 Fourth Quarter Earnings Conference Call Tuesday, February 14, 2023, 5:00 p.m. ET (GlobeNewswire)
06:37AM	Quite a few insiders invested in OraSure Technologies, Inc. (NASDAQ:OSUR) last year which is positive news for shareholders (Simply Wall St.)
Dec-21-22 07:52AM	Investors in OraSure Technologies (NASDAQ:OSUR) have unfortunately lost 74% over the last five years (Simply Wall St.)
Dec-01-22 07:05AM	OraSure Technologies Continues its Dedication to Ending the HIV Epidemic (GlobeNewswire)
Nov-14-22 07:05AM	OraSure Technologies to Present at Stephens Annual Investment Conference (GlobeNewswire)
Nov-08-22 06:05PM	OraSure Technologies (OSUR) Q3 Earnings and Revenues Top Estimates (Zacks)
04:05PM	OraSure Reports 3Q22 Record Revenue of $116.5 Million Growing 116% Year-Over-Year (GlobeNewswire)
Nov-03-22 09:15AM	OraSure Technologies Receives General Clearance for its ORAcollect®Dx Device for Over-the Counter (OTC) Use from the U.S. Food and Drug Administration (FDA) (GlobeNewswire)
Nov-02-22 07:05AM	InteliSwab® COVID-19 Rapid Test Now Available in Amazons Online Store (GlobeNewswire)
Nov-01-22 07:05AM	2022 Third Quarter Earnings Conference Call Tuesday, November 8, 2022, 5:00 p.m. ET (GlobeNewswire)
Oct-07-22 09:14AM	3 Penny Stocks That Are Too Cheap to Ignore (InvestorPlace)
Oct-01-22 10:30AM	Is OraSure Technologies (NASDAQ:OSUR) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Sep-28-22 10:28AM	OraSure Secures BARDA Funding For Next-Gen Ebola Diagnostic Test (Benzinga) +9.84%
07:05AM	OraSure Technologies Receives $8.6 Million BARDA Contract to Develop 2nd Generation Ebola Test (GlobeNewswire)
Sep-20-22 04:05PM	OraSure Wins Contract to Supply Together Take Me Home, HIV Self-Testing Initiative Sponsored by the Centers for Disease Control and Prevention (GlobeNewswire)
Sep-14-22 07:05AM	OraSure Partners with Mars Petcare in One of the Largest Ever Microbiome Studies to Evaluate Pet Health (GlobeNewswire)
Aug-31-22 06:29AM	Independent Director Ronny Lancaster Just Bought 91% More Shares In OraSure Technologies, Inc. (NASDAQ:OSUR) (Simply Wall St.)
Aug-14-22 08:28AM	Analysts Just Published A Bright New Outlook For OraSure Technologies, Inc.'s (NASDAQ:OSUR) (Simply Wall St.)
Aug-09-22 07:25PM	OraSure Technologies (OSUR) Reports Break-Even Earnings for Q2 (Zacks)
04:05PM	OraSure Reports 2Q22 Record Revenue of $80.2 Million Growing 39% Year-Over-Year (GlobeNewswire)
Aug-02-22 07:05AM	OraSure Technologies to Hold 2022 Second Quarter Earnings Conference Call Tuesday, August 9, 2022, 5:00 p.m. ET (GlobeNewswire)
Jul-28-22 07:05AM	OraSures Ongoing Commitment to End the Hepatitis C Epidemic Heats Up at the Racetrack (GlobeNewswire)
Jul-14-22 08:42AM	OraSure Technologies (NASDAQ:OSUR) shareholders have endured a 84% loss from investing in the stock five years ago (Simply Wall St.)
07:05AM	OraSure Technologies Launches New Product for Microbiome Researchers to Study DNA and RNA (GlobeNewswire)
Jun-14-22 08:31AM	Does This Valuation Of OraSure Technologies, Inc. (NASDAQ:OSUR) Imply Investors Are Overpaying? (Simply Wall St.)
Jun-08-22 04:05PM	OraSure Technologies Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -9.01%
May-25-22 07:05AM	InteliSwab® COVID-19 Rapid Test Selected by Federal Government for Nationwide School Testing (GlobeNewswire)
May-23-22 04:05PM	Carrie Eglinton Manner Appointed Chief Executive Officer of OraSure (GlobeNewswire)
May-17-22 07:05AM	InteliSwab® COVID-19 Rapid Test Validated to Detect the Omicron BA.2, BA.2.12.1, BA.3 and BA.5 Subvariants (GlobeNewswire)
May-10-22 06:55PM	OraSure Technologies (OSUR) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.56%
04:05PM	OraSure Reports 1Q22 Record Revenue of $67.7 Million; +16% Year-Over-Year With 21% Growth in Non-COVID Revenue (GlobeNewswire)
May-04-22 06:45PM	PetIQ (PETQ) Q1 Earnings and Revenues Top Estimates (Zacks)
May-03-22 04:05PM	OraSure Technologies, Inc. 2022 First Quarter Earnings Conference Call Tuesday, May 10, 2022, 5:00 p.m. ET (GlobeNewswire)
Apr-24-22 10:21AM	We're Not Very Worried About OraSure Technologies' (NASDAQ:OSUR) Cash Burn Rate (Simply Wall St.)
Apr-07-22 07:05AM	OraSure Technologies Subsidiary DNA Genotek Launches the First Device with De Novo Authorization from the FDA for the Preservation and Stabilization of Microbiome Samples (GlobeNewswire)
Mar-31-22 07:05AM	OraSure Technologies Subsidiary Diversigen Launches Metatranscriptomic Sequencing and Analysis Services for Gut Microbiome Samples (GlobeNewswire)
Mar-22-22 04:05PM	OraSure Director Nancy Gagliano Selected to Serve as Interim Chief Executive Officer; Brings Extensive Diagnostics and Healthcare Leadership Experience to Role (GlobeNewswire)
Feb-23-22 04:05PM	OraSure Technologies Reports 4Q21 Revenue of $63.6 Million; InteliSwab® Production Scales Up (GlobeNewswire)
Feb-16-22 04:05PM	OraSure Technologies, Inc. 2021 Fourth Quarter Earnings Conference Call Wednesday, February 23, 2022, 5:00 p.m. ET (GlobeNewswire)
Jan-31-22 07:54AM	OraSure said its rapid COVID-19 tests can now be used in children (MarketWatch)
07:05AM	InteliSwab® COVID-19 Rapid Tests Receive U.S. FDA Authorization for Pediatric Use and Company Launches New InteliSwab® Connect Reporting App (GlobeNewswire)
Jan-25-22 07:05AM	OraSure Technologies, Inc. Expands HIV Oral Swab In-home Test into Europe (GlobeNewswire)
Jan-24-22 10:04AM	OraSure Technologies (NASDAQ:OSUR) shareholders have endured a 36% loss from investing in the stock a year ago (Simply Wall St.)
Jan-19-22 05:38PM	Peoples Financial Services Corp. Buys Danaher Corp, Goldman Sachs Group Inc, Thermo Fisher ... (GuruFocus.com)
Jan-13-22 04:05PM	InteliSwab® COVID-19 Rapid Tests Detect Omicron at Same Level as Other Variants (GlobeNewswire)

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offer oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in May 2000 in and is headquartered in Bethlehem, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Weber Kathleen Gallagher	Chief Product Officer	Dec 19 '23	Option Exercise	5.71	4,129	23,597	278,829	Dec 21 04:04 PM
Weber Kathleen Gallagher	Chief Product Officer	Dec 19 '23	Sale	8.05	24,129	194,219	254,700	Dec 21 04:04 PM
Anthony Michele Marie	SVP Finance & CAO	Aug 15 '23	Option Exercise	5.71	1,758	10,038	87,946	Aug 17 04:27 PM
Anthony Michele Marie	SVP Finance & CAO	Aug 15 '23	Sale	6.50	1,758	11,427	86,188	Aug 17 04:27 PM
McGrath Kenneth J	Chief Financial Officer	May 30 '23	Buy	4.93	100,000	492,810	285,512	May 31 04:14 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

LRMR

Larimar Therapeutics Inc

OSUR

Orasure Technologies Inc.

Upgrade your FINVIZ experience